Trial Profile
A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2023
Price :
$35
*
At a glance
- Drugs Ubenimex (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms LIBERTY2
- Sponsors Eiger BioPharmaceuticals, Inc.
- 13 Sep 2018 Status changed from active, no longer recruiting to discontinued due the failure to demonstrate efficacy in EIG-UBX-001, the sponsor decided to terminate Study EIG-UBX-002.
- 31 Jan 2018 Planned End Date changed from 1 Jul 2018 to 1 Nov 2018.
- 31 Jan 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Jul 2018.